English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/61296
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorSchaefer, Karl-Ludwig-
dc.contributor.authorHerrero-Martín, David-
dc.date.accessioned2012-11-27T12:44:24Z-
dc.date.available2012-11-27T12:44:24Z-
dc.date.issued2008-
dc.identifierdoi: 10.1016/j.ejca.2008.01.020-
dc.identifierissn: 0959-8049-
dc.identifier.citationEuropean Journal of Cancer 44(5): 699-709 (2008)-
dc.identifier.urihttp://hdl.handle.net/10261/61296-
dc.description.abstractIn Ewing's sarcoma family of tumours (ESFT), the clinically most adverse prognostic parameters are the presence of tumour metastasis at time of diagnosis and poor response to neoadjuvant chemotherapy. To identify genes differentially regulated between metastatic and localised tumours, we analysed 27 ESFT specimens using Affymetrix microarrays. Functional annotation of differentially regulated genes revealed 29 over-represented pathways including PDGF, TP53, NOTCH, and WNT1-signalling. Regression of primary tumours (n = 20) induced by polychemotherapy was found to be correlated with the expression of genes involved in angiogenesis, apoptosis, ubiquitin proteasome pathway, and PI3 kinase and p53 pathways. These findings could be confirmed by in vitro cytotoxicity assays. A set of 46 marker genes correctly classifies these 20 tumours as responding versus non-responding. We conclude that expression signatures of initial tumour biopsies can help to identify ESFT patients at high risk to develop tumour metastasis or to suffer from a therapy refractory cancer.-
dc.description.sponsorshipThis work was supported by grants from the ‘Forschungskommission der Medizinischen Fakultaet Duesseldorf’, and the ‘Madeleine Schickedanz-KinderKrebs-Stiftung’. The Departments of Pathology (Heinrich-Heine-University, Duesseldorf, Germany) and the Laboratory of Molecular Pathology (Universidad de Salamanca-CSIC, Spain) are partners of the EuroBoNeT consortium, a European Commission granted Network of Excellence for studying the pathology and genetics of bone tumours. -
dc.language.isoeng-
dc.publisherElsevier-
dc.rightsclosedAccess-
dc.titleMicroarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy-
dc.typeartículo-
dc.identifier.doi10.1016/j.ejca.2008.01.020-
dc.date.updated2012-11-27T12:44:25Z-
dc.description.versionPeer Reviewed-
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.